Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.80 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.80 |
| ▸ | TNF | P01375 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31722842 | 1.00 | CYP11B1 (0.80) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL12531261 | 0.92 | CYP11B1 (0.74) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL230002 | 0.89 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL31357411 | 0.89 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL30930526 | 0.89 | CYP11B1 (0.69) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL28326064 | 0.89 | CYP11B1 (0.73) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL14817163 | 0.89 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL2025143 | 0.89 | CYP11B1 (0.69) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL28326060 | 0.89 | CYP11B1 (0.69) | CYP11B1CYP11B2TNFALDH1A1HTT | |
| SCHEMBL28325028 | 0.89 | CYP11B1 (0.69) | CYP11B1CYP11B2TNFALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | claimed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | claimed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | claimed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | claimed |
| US-7655323-B2 | That can stabily emit light with various spectra, including high energy blue spectra; tris(1-(2'-(9',9'-dimethyl)fluorenyl)-3-methyl-imidazolin-2-ylidene-C,C3') iridium(III); organic light emitting devices | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655322-B2 | improved stability and efficiency | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655322-B2 | improved stability and efficiency | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655323-B2 | That can stabily emit light with various spectra, including high energy blue spectra; tris(1-(2'-(9',9'-dimethyl)fluorenyl)-3-methyl-imidazolin-2-ylidene-C,C3') iridium(III); organic light emitting devices | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655323-B2 | That can stabily emit light with various spectra, including high energy blue spectra; tris(1-(2'-(9',9'-dimethyl)fluorenyl)-3-methyl-imidazolin-2-ylidene-C,C3') iridium(III); organic light emitting devices | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655322-B2 | improved stability and efficiency | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-02-02 | — | — | US | disclosed |
| US-20050260444-A1 | OLEDs utilizing macrocyclic ligand systems | SOUTHERN CALIFORNIA, UNIVERSITY OF, THE | 2005-11-24 | — | — | US | disclosed |
| US-20050260445-A1 | OLEDs utilizing macrocyclic ligand systems | UNIVERSITY OF SOUTHERN CALIFORNIA,THE | 2005-11-24 | — | — | US | disclosed |
| US-6569880-B2 | Guanidine derivatives | NEUROSEARCH A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | disclosed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | disclosed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | disclosed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | disclosed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | CYP11B1 384/4885CYP11B2 309/4885TNF 904/4885 |
| US-20020049246-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | CYP11B1 384/4885CYP11B2 309/4885TNF 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.